Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF) - Chen, Xuejun; Williams, William V; Sandor, Victor; Yeleswaram, Swamy (Journal of clinical pharmacology, 2013)
Keywords: Aged; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Janus Kinases - antagonists & inhibitors; Male; Models, Biological; Polycythemia Vera - drug therapy; Polycythemia Vera - metabolism; Primary Myelofibrosis - drug therapy; Primary Myelofibrosis - metabolism; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - therapeutic use; Pyrazoles - administration & dosage; Pyrazoles - pharmacokinetics; Randomized Controlled Trials as Topic; Thrombocythemia, Essential - drug therapy; Thrombocythemia, Essential - metabolism